



Biotech Daily

Monday October 19, 2026

Daily news on ASX-listed biotechnology companies

- * ASX UP, BIOTECH DOWN: SYNTARA UP 5%; CURVEBEAM DOWN 12.5%
- * PRO MEDICUS \$24m BILLINGS CLINIC VISAGE DEAL
- * PACIFIC EDGE H1 CXBLADDER TESTS DOWN 30% TO 9k
- * CRYOSITE Q1 REVENUE UP 18% TO \$4.6m
- * BCAL VERSUS GENETIC SIGNATURES
- * AUDEARA 1st CLINICO AURACAST TAIWAN ORDER COMPLETE
- * INVION PHASE I INV043 SKIN CANCER TRIAL 'NO ADVERSE EVENTS'
- * IMUGENE: 'MORE COMPLETE, PARTIAL AZER-CEL RESPONSES'
- * RENERVE: 'NERVALIGN NGM STRONG NERVE REGENERATION, IN SHEEP'
- * ISLAND SCREENS US ARMY GALIDESIVIR ANIMAL STUDY
- * ALGORAE 2 UMEDICA UNNAMED PRODUCT SUPPLY DEALS
- * ADALTA \$230k FEDERAL R&D TAX INCENTIVE; MORE TO COME
- * SOMNOMED 3m BOARD OPTIONS AGM; PRICE TO REPLACE CHAIR RUSSO
- * MAYNE 'NON-ENDORSED' DIRECTOR DR BRETT WELLS AGM
- * AUSTRALIAN ETHICAL TAKES 7% OF AROA
- * DIMERIX DIRECTOR HUGH ALSOP TO REPLACE CHAIR MARK DIAMOND
- * BOTANIX LOSES DIRECTORS DR STEWART WASHER, DANNY SHARP
- * BIOTRON APPOINTS DR MICHAEL THURN DIRECTOR

MARKET REPORT

The Australian stock market was up 0.44 percent on Monday October 19, 2026, with the ASX200 up 39.0 points to 8,845.7 points.

Seven of the Biotech Daily Top 40 companies were up, 24 fell, seven traded unchanged and two were untraded.

Syntara was the best, up 0.1 cents or 5.3 percent to 2.0 cents, with 1.8 million shares traded.

Lumos climbed 4.5 percent; EBR, Micro-X, Nanosonics and Nova Eye were up more than three percent; Actinogen rose 2.2 percent; with Cochlear, CSL and Pro Medicus up by one percent or more.

Curvebeam led the falls, down 0.3 cents or 12.5 percent to 2.1 cents, with 3.9 million shares traded.

Mesoblast lost 11.1 percent; Botanix was down 7.7 percent; 4D Medical, Imugene, Prescient, Resonance and Saluda were down more than five percent; Avita, Clarity, Dimerix and Proteomics fell four percent or more; Alcidion, Artrya, Optiscan and Orthocell were down three percent or more; Emvision, Imricor, Neuren and Telix shed more than two percent; Medical Developments was down 1.2 percent; with Clinuvel, Polynovo, Racura and Resmed down by less than one percent.

PRO MEDICUS

Pro Medicus says it has a \$24 million, seven-year contract with Montana's Billings Clinic Logan Health for its Visage 7 Viewer, Workflow and Open Archive.

Pro Medicus said Billings Clinic Logan Health was "a unified, not-for-profit independent health system with 25 hospitals and more than 1,000 beds, including 16 regional partnerships with critical access hospitals and clinics".

The company said the Visage contract would be implemented in the internet cloud and included the 'full stack' Viewer, Workflow and Open Archive modules "providing a single, unified enterprise imaging platform".

Pro Medicus said that the agreement included migration of legacy picture archiving and communication system (PACS) archives to Visage 7 Open Archive, as well as the distribution of images integrated into Billings Clinic Logan Health's electronic health record system.

The company said that planning would begin "immediately" with implementation expected by April 2027.

Pro Medicus managing-director Dr Sam Hupert said that Billings Clinic Logan Health provided "comprehensive community-focused care to patients across a broad, multi-state, rural area".

"We continue to grow our North American footprint across a very broad range of market opportunities, confirming our belief that our platform is ideally suited to meet the needs of the vast majority of the total addressable market," Dr Hupert said. "This is reflected in our pipeline, which remains strong and spans all market segments."

Pro Medicus was up \$1.91 or 1.1 percent to \$177.64 with 297,054 shares traded.

PACIFIC EDGE

Pacific Edge says Cxbladder bladder cancer tests for the six months to September 30, 2026 fell 30.4 percent to 9,184, compared to the previous corresponding period.

Last year, Pacific Edge said Cxbladder test sales for the six months to September 30, 2025 fell 7.3 percent to 13,191 tests; and in July, said tests for the three months to June 30, 2026 fell 34.9 percent to 5,116 tests (BD: Oct 14, 2025; Jul 14, 2026).

Today, the company said that US commercial volumes for the three months to September 30, 2026 were down 13.0 percent to 2,867 tests as it “maintained lower commercial spending and repositioned towards reimbursable intermediate risk micro-haematuria patients”.

Pacific Edge said the US result was “partly offset by a 3.7 percent increase in [Asia Pacific] commercial volumes to 1,201 tests”.

The company said the US Centers for Medicare and Medicaid Services proposed price increased for Cxbladder Monitor and Cxbladder Triage by 35.0 percent and 39.2 percent, respectively, from \$US760 (\$A1,091) each, to \$US1,026 (\$A1,473) and \$US1,058 (\$A1,519), respectively, subject to finalization on January 1, 2027.

Pacific Edge said Cxbladder gained in-network coverage at Blue Cross plans in North and South Carolina from November 1, 2026, which covered about 8,000,000 people.

The company said Triage Plus sales continued to increase, representing 5.6 percent of US tests in the three-month period and 10.8 percent of tests in September 2026 compared to 0.8 percent in the three months to June 30, 2026.

Pacific Edge said it had reached the enrolment target of about 2,000 patients for the Triage Plus concordance study.

Pacific Edge chief executive officer Dr Peter Meintjes said that “final Medicare coverage remains the critical near-term milestone”.

“We continue to expect the policy to be finalized by the end of this calendar year,” Dr Meintjes said.

In May, Pacific Edge rose 44.8 percent on the publication of a draft local coverage determination (LCD) with explicit coding guidance for its Cxbladder Triage and Triage Plus and final determination expected within 12 months (BD: May 15, 2026).

Today, Dr Meintjes said that “in the meantime, US volumes continue to reflect our disciplined approach to spending and the transition towards reimbursable patients”.

Pacific Edge was unchanged at 19 cents.

CRYOSITE

Cryosite says revenue from the three months to September 30, 2026 rose 17.95 percent to \$4.6 million and the TGA has conducted audits of its two sites.

Cryosite said revenue was from its cold, frozen and cryofreeze storage and transport services for clinical trial, pharmaceutical and biological products.

The company said net profit after tax was up 16.7 percent to \$700,000 for the three months, with expenses increasing below the rate of revenue, “resulting in a greater proportion of each additional dollar of revenue reaching earnings”.

Cryosite said the Australian Therapeutic Goods Administration had conducted an audit of its facilities, which “for the first time” included both its South Granville headquarters and additional Auburn site, with an outcome expected “in the coming months”.

Last year, the company said it had paid \$9.5 million to acquire 100-104, Adderley Street West, Auburn warehouse, “more than doubling” its national storage capacity to support revenue growth and mitigate capacity bottlenecks (BD: Oct 1, Nov 27, 2025).

Cryosite was untraded at \$1.205.

BCAL DIAGNOSTICS, GENETIC SIGNATURES

After the market closed on Friday, Genetic Signatures asked Bcal Diagnostics to clarify whether it intended to merge with Genetic Signatures.

Last month, Genetic Signatures said that it opposed a Bcal request, under the Corporations Act section 249D, to replace chair Michael Aicher and director Dr Jenny Harry with former Genetic Signatures chief executive officer Dr John Melki and Susan Forrester (BD: Sep 3, 23, 2026).

Genetic Signatures (GSS) said on Friday, that if the section 249D Bcal proposed directors, Dr Melki and Ms Forrester, were elected at the October 28 extraordinary general meeting “and represent the majority of GSS directors at that time” the existing Genetic Signatures directors would resign.

According to Commsec data, Genetic Signatures currently has three directors: executive chair Michael Aicher and non-executive directors Dr Jenny Harry and Anne Lockwood. Genetic Signatures provided tables showing that it and its proposed merger partner Microba Life Sciences each had about \$15 million in revenue in the past two financial years compared to Bcal, which Genetic Signatures said had \$182,510 in revenue in 2025-'26 and \$21,637 in 2024-'25.

Genetic Signatures said that it had \$20.9 million in cash at September 30, 2026 and Bcal had \$1.6 million at June 30, 2026.

In a letter to Genetic Signatures shareholders, Bcal said that it was Genetic Signatures' largest shareholder with 18.5 percent of the company.

In July, Bcal said it became substantial in Genetic Signatures with 23,173,644 shares (10.2%), acquiring the shares for \$1,390,119 or six cents a share (BD: Jul 3, 2026).

In August, Bcal said it had increased its Genetic Signatures holding from 23,173,644 shares (10.2%) to 41,923,644 shares (18.46%) saying it bought 18,750,000 shares, off-market, for \$1,500,000 or eight cents a share (BD: Aug 26, 2026).

Bcal said that there had been a “significant diminution of shareholder value” with Genetic Signatures' share price falling “circa 80 percent or more during the period in which Mike Aicher and Jenny Harry have been on the board” and provided graphs of the Genetic Signatures share price to support the argument.

Bcal said that the share price decline was “a compelling reason for GSS shareholders to scrutinize the GSS board's strategy and execution”.

“If this is ‘oversee[ing] the integrity of [GSS's] business operations’ as GSS claims on its web site, then Bcal wants no more of it, and nor should other GSS shareholders,” the company said.

Bcal was untraded at 7.9 cents.

Genetic Signatures was up 0.4 cents or five percent to 8.4 cents.

AUDEARA

Audeara says it has launched its Clinico-branded Auracast audio suite in Taiwan, with first orders shipped and deployed at Taichung's Chung Shan Medical University.

Earlier this year, Audeara said it had \$164,000 in introductory orders from Taipei, Taiwan's Clinico for two Auracast-enabled audio hearing devices and its BT-03 audio broadcaster platform (BD: Mar 9, 2026).

Today, the company said Clinico had donated 20 systems to Chung Shan Medical University for teaching and campus use and that the deployment provided a “live institutional reference for Auracast in education and demonstrates the scalability of Audeara technology through partner-branded products”.

Audeara was up 0.2 cents or 8.3 percent to 2.6 cents.

INVION

Invion says 14 patient readouts from its phase I trial of INV043 for non-melanoma skin cancer show “no serious adverse events, dose-limiting toxicities or pain”.

Last year, Invision said that its safety committee identified no adverse events following the treatment of the first six patients in its at-least 18-patient, phase I/II trial of INV043 for non-melanoma skin cancer at Brisbane’s Veracity Clinical Research

(BD: May 29, 2025).

In April, the company said it had approval to dose patients with basal cell carcinoma in the final part of its phase I/II trial of INV043 for skin cancer (BD: Apr 21, 2026).

Today, an Invision spokesperson told Biotech Daily that “it was 14 ‘readouts’ as a few patients had more than one lesion treated” and said the company was not releasing further details, with final results to be released after the follow-up period.

The company said there were eight cases of mild-to-moderate adverse events, including mild headache, urinary tract infection and skin abrasion, “but all were assessed by the [safety review committee] to be ‘not related’ or ‘unlikely related’ to the treatment”.

Invion said the preliminary findings showed a 79 percent disease control rate and one complete response in the squamous cell carcinoma and basal cell carcinoma lesions.

The company said the trial results would be finalized after the 12-month patient follow-up and independent audit and believed the preliminary findings were “sufficient to meet primary safety endpoints and demonstrate encouraging efficacy signals”.

Invion said the data was reviewed by the safety review committee and supported its decision to conduct a phase II trial.

Invion executive chair Prof Thain Chew said INV043 had “delivered what we hoped to see in a first-in-human study for skin cancer, a strong safety profile and promising early efficacy signals across multiple non-melanoma skin cancer types. Including in both squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) lesions, reinforcing the potential of Photosoft as a differentiated photo-dynamic therapy platform”.

Invion was up 0.4 cents or 11.8 percent to 3.8 cents.

IMUGENE

Imugene says it has an additional complete response and partial response in its ongoing phase Ib basket study of azer-cel for various blood cancers.

Earlier this year, Imugene said that it had enrolled the first Bruton tyrosine kinase (BTK) inhibitor patient in its phase Ib basket study of its azer-cel CAR-T for various blood cancers (BD: May 28, 2026).

Last month, the company said one follicular lymphoma patient in the BTK inhibitor cohort of the study had achieved a complete response; and later, said a second patient with mantle cell lymphoma had a complete response (BD: Jun 30, Jul 1, 2026).

Today, Imugene said the additional complete response was a cohort two patient with marginal zone lymphoma, taking the total overall response rate in cohort two to 81 percent, with 22 of 27 patients achieving a response.

The company said the partial response was a cohort three patient with Richter’s transformation lymphoma who had previously shown stable disease.

Imugene said cohort three was evaluating azer-cel with BTK inhibitor therapy and had an overall response rate of 86 percent, or six of seven patients achieving a response.

The company said the results added to the “clinical evidence supporting azer-cel across diverse B-cell malignancies and patient populations with significant unmet medical need”.

Imugene fell 0.2 cents or 5.6 percent to 3.4 cents with 12.1 million shares traded.

RENERVE

Renerve says 12-month interim results show “strong nerve regeneration and return of nerve function in a 4cm gap’ using Nervalign nerve guide matrix (NGM), in sheep.

Renerve said the study assessed a 4.0 centimetre (cm) section of the Nervalign nerve guide matrix implanted in a peripheral nerve, compared with an autologous nerve graft.

The company said the study included three Nervalign implants and three autologous nerve grafts, with all animals recovering after surgery and walking freely within 12 hours.

Renerve said that at 12 months, animals treated with Nervalign nerve guide matrix “showed similar gait to animals treated with an autologous nerve graft and animals that had not undergone the nerve intervention”.

The company said nerve conduction testing at 12 months detected both sensory and motor nerve signals in sheep treated with nerve guide matrix, showing that nerve signals travelled across the repaired area, similarly to autologous nerve grafts.

Renerve said in one animal implanted with nerve guide matrix “a minimal area of inflammation was observed within the implant at 12 months, although axonal regrowth was present throughout the length of that implant ... [which was] “so far unexplained, however could be part of the natural nerve regeneration”.

The company said more animals were scheduled to be implanted in late November 2026 and it expected “to provide a further update once the data from the additional animals and the full analysis are available”.

Renerve was up 0.6 cents or 7.8 percent to 8.3 cents.

ISLAND PHARMACEUTICALS

Island says 22 non-human primates have been screened for its galidesivir dose optimization study with the US Army Medical Research Institute of Infectious Diseases.

Last year, Island said it completed its acquisition of the Durham, North Carolina-based Biocryst Pharmaceuticals’ galidesivir anti-viral program (BD: Jul 31, 2025).

Earlier this year, the company said with the US Army Medical Research Institute of Infectious Diseases (Amriid) it would develop galidesivir for Marburg virus under the US Food and Drug Administration animal rule pathway following FDA confirmation of the validity of the regulatory approval pathway (BD: Mar 4, 2026).

Today, Island said the completion of screening and preparation activities confirmed that sufficient qualified animals were available for the planned 20-animal study.

The company said study data was expected to be used for future dose selection and the design of its pivotal confirmatory efficacy study under the FDA animal rule.

Island fell half a cent or 1.45 percent to 34 cents.

ALGORAE PHARMACEUTICALS

Algorae says it has two supply and distribution deals with Mumbai, India’s Umedica Laboratories for eight unnamed molecules and one additional unnamed product.

Algorae said under one agreement it was appointed exclusive importer, distributor and commercial partner in Australia for a portfolio of eight molecules, with Umedica acting as manufacturer and marketing authorization holder.

The company said through a separate licence and supply agreement it would supply an undisclosed Umedica product and would obtain marketing approval and commercialize the product under its own brand in Australia.

Algorae said the financial terms of the agreement were commercial-in-confidence.

Algorae was up 0.1 cents or 11.1 percent to one cent with 1.1 million shares traded.

ADALTA

Adalta says it has received \$230,000 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.

Adalta said the incentive was a first instalment relating to research and development expenditure for the year to June 30, 2026 and that it expected an additional incentive "in excess of \$1 million" related to an advanced overseas finding for work on EW-001, or BZDS-1901, conducted overseas.

In January, the company said its Adcella 'East-to-West' strategy would develop Shanghai Cell Therapy Group's BZDS1901 for mesothelioma outside China; and later, said five of 10 mesothelioma patients treated with EW-001 in a China study were alive and on study, providing a 50 percent overall response rate (BD: Jan 18, Aug 10, 2026).

Adalta managing-director Dr Tim Oldham said the advanced overseas finding recognized "that certain work being done on EW-001 in China that cannot be performed in Australia is an integral part of an Australian [research and development] program".

Adalta was unchanged at 0.3 cents.

SOMNOMED

Somnomed says its annual general meeting will vote to issue 3,050,000 options to managing-director Karen Borg, future chair Andrew Price and two directors.

Separately, Somnomed said chair Guy Russo would retire, effective at the meeting, with non-executive director Mr Price to succeed him as chair.

The company said it had begun a search for an additional non-executive director.

Somnomed said the meeting would vote to issue Ms Borg 1,500,000 zero exercise price options, exercisable by December 6, 2032 and vesting on continued employment without milestones and in addition to her \$682,500 fixed annual remuneration.

The company said investors would vote to issue Mr Price 750,000 options and directors Michael Gordon and Benjamin Gisz 400,000 options, each, exercisable at 50 cents each within four years, in addition to the directors' \$50,000 yearly fees.

Somnomed said investors would vote on the remuneration report, to re-elect directors Mr Gisz and Mr Price, and refresh the non-executive and employee share option plans.

The meeting will be held at Level 1, 111 Harrington Street, Sydney on November 23, 2026 at 3pm (AEDT).

Somnomed was untraded at 23.5 cents.

MAYNE PHARMA

Mayne says its annual general meeting will vote to elect "external non-board endorsed candidate" Dr Brett Wells as a non-executive director.

Mayne said Dr Wells was nominated director by his wife Dr Kenney Wan, a shareholder in the company and said Dr Wells had provided information saying he was an astrophysicist, anaesthetist, aerospace engineer and financial analyst with about two percent of Mayne.

The company said it did not believe the election of Dr Wells was in the best interests of Mayne and recommended shareholders vote against his election, with the chair intending to vote undirected proxies against the resolution.

The company said investors would vote to adopt the remuneration report, elect directors Jacob Ma-Weaver, Meghan Rivera and Bruce Robinson and approve the incentive plan.

The meeting will be held online and at Minter Ellison, Level 20, Collins Arch, 447 Collins Street, Melbourne on November 20, 2026 at 10am (AEDT).

Mayne was up three cents or 1.2 percent to \$2.55.

AROA BIOSURGERY

Sydney's Australian Ethical says it has increased its substantial shareholding in Aroa from 22,011,701 shares (6.36%) to 25,611,701 shares (7.40%).

Australian Ethical said on October 15, 2026 it bought 3,600,000 shares for \$1,784,940, or 49.6 cents a share.

Aroa was unchanged at 51 cents.

DIMERIX

Dimerix says Mark Diamond will retire as chair, effective from October 30, 2026, "to focus on other external commitments", with director Hugh Alsop appointed interim chair.

Dimerix thanked Mr Diamond for his contribution and said Mr Alsop had been a director since 2017.

The company said it was reviewing its board composition and skills required.

Dimerix fell one cent or 4.55 percent to 21 cents with 1.1 million shares traded.

BOTANIX PHARMACEUTICALS

Botanix says Australian non-executive directors Dr Stewart Washer and Danny Sharp have resigned, effective immediately.

Botanix said company secretary Andrew Mickley and chief financial officer Graeme Morissey have been appointed interim non-executive and executive director, respectively.

The company said Mr Bickley had more than 15 years of experience in corporate governance, legal and advisory roles and held a Bachelor of Laws from England's University of Essex.

Botanix said Mr Morissey had been chief financial officer for mining and mineral exploration companies and had worked for EY, KPMG and Grant Thornton, was a director of Heavy Rare Earths and Jacaranda Resources.

The company said Mr Bickley and Mr Morissey would be paid a further \$40,000 a year, each, for taking on the interim director roles, and would stand for election at the annual general meeting on November 30, 2026.

Botanix fell 0.1 cents or 7.7 percent to 1.2 cents with 32.9 million shares traded.

BIOTRON

Biotron says it has appointed Dr Michael Thurn as a director, effective from today.

Biotron said Dr Thurn had more than 25 years of experience in drug discovery, pre-clinical and clinical development, regulatory strategy, capital raising and licencing, was a former Australian Therapeutic Goods Administration toxicologist and Neurizon (formerly Pharmaust) managing-director.

The company said Dr Thurn was an Arovella director and Erasca Australia director, a Bellberry human research ethics committee reviewer and had held executive roles at Botanix, Mimetica, Spinifex Pharmaceuticals, Cytopia Research and Xenome.

Biotron said Dr Thurn held a Bachelor of Applied Science and a Doctor of Philosophy from the University of Technology Sydney.

Biotron was unchanged at 0.2 cents.